Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 10, 2023

BUY
$2.49 - $20.59 $49,521 - $409,493
19,888 Added 42.89%
66,254 $178,000
Q1 2023

May 11, 2023

BUY
$15.95 - $25.18 $739,537 - $1.17 Million
46,366 New
46,366 $865,000
Q3 2021

Nov 12, 2021

SELL
$10.18 - $26.64 $172,998 - $452,720
-16,994 Closed
0 $0
Q2 2021

Aug 12, 2021

SELL
$18.57 - $35.68 $6,202 - $11,917
-334 Reduced 1.93%
16,994 $453,000
Q1 2021

May 14, 2021

SELL
$31.0 - $55.72 $47,430 - $85,251
-1,530 Reduced 8.11%
17,328 $601,000
Q4 2020

Feb 09, 2021

BUY
$37.09 - $48.97 $70,545 - $93,140
1,902 Added 11.22%
18,858 $699,000
Q3 2020

Nov 13, 2020

SELL
$40.47 - $45.5 $88,831 - $99,872
-2,195 Reduced 11.46%
16,956 $697,000
Q2 2020

Aug 03, 2020

BUY
$32.57 - $42.83 $99,761 - $131,188
3,063 Added 19.04%
19,151 $776,000
Q1 2020

May 15, 2020

SELL
$23.3 - $45.96 $155,737 - $307,196
-6,684 Reduced 29.35%
16,088 $559,000
Q4 2019

Feb 18, 2020

BUY
$34.58 - $48.06 $101,111 - $140,527
2,924 Added 14.73%
22,772 $977,000
Q3 2019

Nov 12, 2019

SELL
$36.98 - $48.45 $23,519 - $30,814
-636 Reduced 3.1%
19,848 $734,000
Q2 2019

Aug 13, 2019

SELL
$35.13 - $55.53 $62,426 - $98,676
-1,777 Reduced 7.98%
20,484 $925,000
Q1 2019

May 15, 2019

BUY
$42.83 - $59.91 $2,227 - $3,115
52 Added 0.23%
22,261 $1.21 Million
Q4 2018

Feb 14, 2019

SELL
$37.97 - $60.16 $205,911 - $326,247
-5,423 Reduced 19.63%
22,209 $1.03 Million
Q3 2018

Nov 13, 2018

BUY
$56.3 - $67.25 $1.56 Million - $1.86 Million
27,632 New
27,632 $1.68 Million

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $31.9M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Profund Advisors LLC Portfolio

Follow Profund Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.